Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Liraglutide and Semaglutide Market

Liraglutide and Semaglutide Market Trends

Report ID: GMI5886
Published Date: May 2023
Report Format: PDF

Download Free Sample

Liraglutide and Semaglutide Market Trends

Obesity is one of the major risk factors contributing to the higher prevalence of diabetes, thus propelling the demand for liraglutide and semaglutide. Obesity leads to increased levels of inflammation and fatty acids that result in insulin resistance causing the risk of type 2 diabetes. Thus, increasing obesity rates globally has created significant demand for effective treatments for weight management and related health conditions. Also, positive results in maintaining blood sugar control, blood pressure and cholesterol levels have significantly demonstrated potential therapeutic applications. Thus, increasing awareness regarding diabetes, obesity related health conditions and favourable government initiatives for preventive healthcare is expected to boost the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of liraglutide and semaglutide accounted for over USD 14 billion in 2022 and is estimated to cross USD 41 billion by 2032, on account of increasing prevalence diabetes and rising awareness regarding obesity, as the products are used primarily in the treatment of type 2 diabetes and obesity.

The type 2 diabetes mellitus segment is expected to grow at a 11.4% CAGR during 2023 and 2032, owing to product ability to effectively control blood sugar levels by stimulating insulin release and reducing the production of glucagon.

North America accounted for over 71% of the market share in 2022 and is anticipated to grow at considerable rate through 2032, backed by increasing occurrence of diabetes and rising awareness regarding the importance of disease management.

Novo Nordisk A/S, HEC Pharma Co., Shenzhen JYMed Technology Co. Ltd., Bachem Holding AG among others.